[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gariti et al., 1999 - Google Patents

Cotinine replacement levels for a 21 mg/day transdermal nicotine patch in an outpatient treatment setting

Gariti et al., 1999

View HTML
Document ID
10531480592167698968
Author
Gariti P
Alterman A
Barber W
Bedi N
Luck G
Cnaan A
Publication year
Publication venue
Drug and alcohol dependence

External Links

Snippet

This study examined plasma cotinine replacement levels of 56 outpatient smokers administered a 21 mg/day transdermal nicotine patch (Nicoderm CQ®). The percentage of cotinine replacement ranged from 35 to 232%(mean 107%; median 90.5%). Four subject …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications

Similar Documents

Publication Publication Date Title
Back et al. Reactivity to laboratory stress provocation predicts relapse to cocaine
Gruber et al. Neuropsychological consequences of opiate use
Fatseas et al. Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals
Mintzer et al. Opioid abuse and cognitive performance
Ray et al. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine
Kampman et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms
Margolese et al. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences
Kampman et al. A pilot trial of olanzapine for the treatment of cocaine dependence
George et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia
Konstenius et al. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24‐week randomized placebo‐controlled trial
Donny et al. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self‐administration in opioid‐dependent volunteers
LaRowe et al. Reactivity to nicotine cues over repeated cue reactivity sessions
Martinez et al. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study
Castells et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta‐analysis of randomized controlled clinical trials
Rademacher et al. Effects of smoking cessation on presynaptic dopamine function of addicted male smokers
JPH09508967A (en) How to monitor if a patient is following a drug prescription
Gariti et al. Detecting smoking following smoking cessation treatment
Winhusen et al. Achieving smoking abstinence is associated with decreased cocaine use in cocaine-dependent patients receiving smoking-cessation treatment
Schmitz et al. The effects of high and low doses of methadone on cigarette smoking
Altamirano et al. Interaction between family history of alcoholism and locus of control in the opioid regulation of impulsive responding under the influence of alcohol
Pace et al. Substance use disorders
Donny et al. Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming
Kampman et al. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence
McRae-Clark et al. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
Hatsukami et al. Self-administration of smoked cocaine.